USPTO Issues Notice of Allowance for IRLAB Therapeutics’ IRL1117 Patent
IRLAB Therapeutics said the patent grant remains pending administrative formalities, with protection expected into the early 2040s.
IRLAB Therapeutics said the patent grant remains pending administrative formalities, with protection expected into the early 2040s.